COMMUNIQUÉS West-GlobeNewswire

Sonablate Expands Leadership to Accelerate Growth in Incision-Free Prostate Care Solutions
09/04/2026
Appointments support rising demand for HIFU and advance the “precision sound medicine” platform across new clinical applications CHARLOTTE, N.C., April 09, 2026 (GLOBE NEWSWIRE) -- Sonablate , a global leader in focused [...]
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
09/04/2026
SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that it will share new data at the Society of [...]
Cardiology Consultants of Philadelphia Launches CCP Now, a Specialized Cardiac Walk-In Facility in Delaware County
09/04/2026
SPRINGFIELD, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Cardiology Consultants of Philadelphia (CCP), the region’s leading cardiology practice, today announced the grand opening of CCP Now, a cardiac walk-in facility [...]
The Science Behind Glycocalyx Support: Why Rhamnan Sulfate Is Different
09/04/2026
Rhamnan sulfate is a marine-derived polysaccharide specifically studied for its structural affinity to the endothelial glycocalyx, the lining inside every blood vessel. Calroy holds patents on microfluidic chip [...]
Cures Within Reach Approves Five Clinical Trials at Chicago-based Research Institutions
09/04/2026
Clinical trials are led by early-stage investigators and/or impact health equity, veterans and pediatrics Future funding increased to offset cuts in medical research funding CHICAGO, April 09, 2026 (GLOBE NEWSWIRE) -- [...]
Çakırtepe Hospital Performs Its First UBE Spine Surgery in Ünye
09/04/2026
ÜNYE, Türkiye, April 09, 2026 (GLOBE NEWSWIRE) -- Çakırtepe Hospital , located on Türkiye’s Black Sea coast in Ünye, has achieved a new milestone in advanced spine care by performing its first UBE (Unilateral Biportal [...]
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
09/04/2026
• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D • Scott Platshon appointed as Chief Business Officer VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a [...]
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
09/04/2026
Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted Antibodies C4T to [...]
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
09/04/2026
TORONTO and HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
Nkarta to Participate in Needham Virtual Healthcare Conference
09/04/2026
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune [...]
Seres Therapeutics to Present at CARB-X Investor Day
09/04/2026
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X [...]
Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain
09/04/2026
Publication strengthens NetraMark's case for biomarker-guided enrichment, individualized response modeling, and explainable AI for trial design in psychedelic clinical development. TORONTO, April 09, 2026 (GLOBE [...]
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
09/04/2026
KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences WATERTOWN, Mass., April 09, 2026 ( [...]
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
09/04/2026
TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat [...]
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
09/04/2026
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics [...]
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
09/04/2026
New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer Preclinical characterization of FHT-171, [...]
Soleo Health Opens New Ambulatory Infusion Center in Austin, Texas
09/04/2026
FRISCO, Texas and AUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today the opening of its new ambulatory [...]
Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
09/04/2026
The financing combines a $50M Series D investment by Boehringer Ingelheim with additional dedicated funding to support commercialization. As part of the agreement, Boehringer is transferring responsibility for [...]
Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours
09/04/2026
Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets This is OBT’s third major pharma [...]

Pages